New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology1 support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
As awareness and clinical support for PROGENSA PCA3 grows, a unique new resource regarding prostate cancer has been launched. www.PCA3.org is the first patient and professional website dedicated solely to PCA3, providing patients and healthcare professionals with information about how PCA3 can be used to help tackle the UK's most common cancer affecting males.
Read full story at Medical News Today.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment